Literature DB >> 10905527

Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women.

L Ahdieh1, A Muñoz, D Vlahov, C L Trimble, L A Timpson, K Shah.   

Abstract

Increased risk for cervical intraepithelial neoplasia (CIN) in human immunodeficiency virus (HIV)-infected women may be explained by repeated positivity of human papillomavirus (HPV) infection facilitated by HIV infection and related immunosuppression. As part of a longitudinal study with semiannual examinations, 268 women in Baltimore, Maryland (of whom 184 were HIV+), provided 1,426 cervicovaginal lavage specimens tested for HPV DNA by a polymerase chain reaction-based assay between 1992 and 1998. HPV positivity and time to HPV clearance according to HIV serostatus and CD4+ cell count were compared using models for correlated binary data and survival analysis. Of the 187 participants who had at least one positive measurement, the probability of subsequent HPV positivity among HIV- women and HIV+ women with CD4+ > or =200 and <200 cells/microl was 47.5%, 78.7%, and 92.9% (p < 0.001). Within-women HPV results were correlated (i.e., clustered) in each group (p < 0.01). Compared with HIV-participants, the relative incidence of HPV clearance was 0.29 and 0.10 among HIV+ women with CD4+ > or =200 and <200 cells/microl (p < 0.001). At the end of follow-up, 11 women had biopsy-confirmed CIN. The association of HIV and CIN (p = 0.014) was fully explained by repeated HPV positivity induced by HIV infection (p = 0.648). Reversal of immunosuppression following potent antiretroviral therapy must be expected to have a dramatic impact on HIV-related CIN.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10905527     DOI: 10.1093/oxfordjournals.aje.a010165

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  44 in total

1.  Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women.

Authors:  Cecile D Lahiri; Katherine B Dugan; Xianhong Xie; Laura Reimers; Robert D Burk; Kathryn Anastos; Leslie Stewart Massad; Isam-Eldin Eltoum; Xiaonan Xue; Gypsyamber DʼSouza; Lisa Flowers; Joel M Palefsky; Lisa Rahangdale; Howard D Strickler; Ighovwerha Ofotokun
Journal:  J Acquir Immune Defic Syndr       Date:  2015-10-01       Impact factor: 3.731

2.  Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.

Authors:  Anne M Neilan; Brad Karalius; Kunjal Patel; Russell B Van Dyke; Mark J Abzug; Allison L Agwu; Paige L Williams; Murli Purswani; Deborah Kacanek; James M Oleske; Sandra K Burchett; Andrew Wiznia; Miriam Chernoff; George R Seage; Andrea L Ciaranello
Journal:  JAMA Pediatr       Date:  2017-05-01       Impact factor: 16.193

3.  Determinants of newly detected human papillomavirus infection in HIV-infected and HIV-uninfected injection drug using women.

Authors:  Darcy F Phelan; Stephen J Gange; Linda Ahdieh-Grant; Shruti H Mehta; Gregory D Kirk; Keerti Shah; Patti Gravitt
Journal:  Sex Transm Dis       Date:  2009-03       Impact factor: 2.830

Review 4.  Incidence and progression of cervical lesions in women with HIV: a systematic global review.

Authors:  Sheri A Denslow; Anne F Rositch; Cynthia Firnhaber; Jie Ting; Jennifer S Smith
Journal:  Int J STD AIDS       Date:  2013-08-29       Impact factor: 1.359

5.  HIV Infection and Survival Among Women With Cervical Cancer.

Authors:  Scott Dryden-Peterson; Memory Bvochora-Nsingo; Gita Suneja; Jason A Efstathiou; Surbhi Grover; Sebathu Chiyapo; Doreen Ramogola-Masire; Malebogo Kebabonye-Pusoentsi; Rebecca Clayman; Abigail C Mapes; Neo Tapela; Aida Asmelash; Heluf Medhin; Akila N Viswanathan; Anthony H Russell; Lilie L Lin; Mukendi K A Kayembe; Mompati Mmalane; Thomas C Randall; Bruce Chabner; Shahin Lockman
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

6.  Influence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa.

Authors:  R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes
Journal:  J Clin Virol       Date:  2013-10-18       Impact factor: 3.168

7.  Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study.

Authors:  Alison G Abraham; Gypsyamber D'Souza; Yuezhou Jing; Stephen J Gange; Timothy R Sterling; Michael J Silverberg; Michael S Saag; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Richard D Moore; Marina B Klein; Mari M Kitahata; Gregory D Kirk; Robert S Hogg; Nancy A Hessol; James J Goedert; M John Gill; Kelly A Gebo; Joseph J Eron; Eric A Engels; Robert Dubrow; Heidi M Crane; John T Brooks; Ronald J Bosch; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

8.  High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil.

Authors:  José E Levi; Bernhard Kleter; Wim G V Quint; Maria C S Fink; Cynthia L M Canto; Regina Matsubara; Iara Linhares; Aluísio Segurado; Bart Vanderborght; José Eluf Neto; Leen-Jan Van Doorn
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study.

Authors:  Jennifer R Moodley; Deborah Constant; Margaret Hoffman; Anna Salimo; Bruce Allan; Ed Rybicki; Inga Hitzeroth; Anna-Lise Williamson
Journal:  BMC Cancer       Date:  2009-08-07       Impact factor: 4.430

10.  Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.

Authors:  Roger J Bedimo; Kathleen A McGinnis; Melinda Dunlap; Maria C Rodriguez-Barradas; Amy C Justice
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.